Skip to content
2000
Volume 25, Issue 5
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Background

Resveratrol (RSV) is used for the treatment of various diseases due to their anti-inflammatory and antioxidant activities. However, its beneficial aspects on viral hepatitis have been less investigated.

Objective

This report reviews the impact of resveratrol on viral hepatitis and chronic viral hepatitis-related hepatocellular carcinoma (HCC).

Methods

The systematic review was performed and reported according to the PRISMA 2020 statement. Several core databases, such as Cochrane Library, PubMed, Web of Science, EMBASE, and Scopus, were used for search on September 6, 2023. After extraction of the data, the desired information of the full text of the studies was recorded in Excel, and the outcomes and mechanisms were reviewed.

Results

RSV inhibits viral replication through anti-HCV NS3 helicase activity, maintains redox homeostasis glutathione (GSH) synthesis, improves T and B cell activity, and suppresses miR-155 expression. It also enhances viral replication by enhancing hepatitis C virus (HCV) RNA transcription, activating sirtuin-1 (SIRT1), which can increase peroxisome proliferator-activated receptor (PPAR), and SIRT1 activates the HBV X protein (HBx). Moreover, RSV is responsible for hepatitis-related HCC proliferation suppression of mammalian target of rapamycin (mTOR), SIRT1 up-regulation, inhibiting expression of HBx, and reducing expression of cyclin D1.

Conclusion

Despite the promising properties of RSV in inhibiting hepatitis-related HCC cell proliferation, its antiviral effects in viral hepatitis are controversial. The anti-hepatitis behaviors of RSV are mainly dose-dependent, and in some studies, activating some hepatoprotective pathways increases the transcription and replication of chronic HBV and HCV. Therefore, healthcare providers should be aware of viral hepatitis before using RSV supplements.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240284347240125072555
2024-02-19
2025-12-09

  • From This Site

    /content/journals/cmm/10.2174/0115665240284347240125072555
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. OdenwaldM.A. PaulS. Viral hepatitis: Past, present, and future.World J. Gastroenterol.202228141405142910.3748/wjg.v28.i14.1405 35582678
     [Google Scholar]
  2. JefferiesM. RauffB. RashidH. LamT. RafiqS. Update on global epidemiology of viral hepatitis and preventive strategies.World J. Clin. Cases201861358959910.12998/wjcc.v6.i13.589 30430114
     [Google Scholar]
  3. FreelandC. RachoR. KamischkeM. Health-related quality of life for adults living with hepatitis B in the United States: A qualitative assessment.J. Patient. Rep. Outcomes20215112110.1186/s41687‑021‑00398‑8 34757456
     [Google Scholar]
  4. SaussakovaS. DauletovaG. NakipovZ. Health-related quality of life in patients with chronic hepatitis B: A Meta-analysis of observational studies.Iran. J. Public Health2023523453462 37124905
     [Google Scholar]
  5. ZarrinA. AkhondiH. Viral Hepatitis.In: StatPearls.Treasure Island, FLStatPearls Publishing2023
     [Google Scholar]
  6. RussoF.P. ZanettoA. PintoE. Hepatocellular carcinoma in chronic viral hepatitis: Where do we stand?Int. J. Mol. Sci.202223150010.3390/ijms23010500 35008926
     [Google Scholar]
  7. RísquezA. EchezuríaL. Carrión-NessiF.S. Forero-PeñaD.A. A time-series analysis of morbidity and mortality of viral hepatitis in Venezuela, 1990-2016.BMC Infect. Dis.202323136110.1186/s12879‑023‑08338‑1 37245003
     [Google Scholar]
  8. TorreP. AglittiA. MasaroneM. PersicoM. Viral hepatitis: Milestones, unresolved issues, and future goals.World J. Gastroenterol.202127284603463810.3748/wjg.v27.i28.4603 34366625
     [Google Scholar]
  9. LamperticoP. AgarwalK. BergT. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.J. Hepatol.201767237039810.1016/j.jhep.2017.03.021 28427875
     [Google Scholar]
  10. DunnR. WettenA. McPhersonS. DonnellyM.C. Viral hepatitis in 2021: The challenges remaining and how we should tackle them.World J. Gastroenterol.2022281769510.3748/wjg.v28.i1.76 35125820
     [Google Scholar]
  11. ZoulimF. Hepatitis B virus resistance to antiviral drugs: Where are we going?Liver Int.201131s111111610.1111/j.1478‑3231.2010.02399.x 21205147
     [Google Scholar]
  12. PanY. XiaH. HeY. ZengS. ShenZ. HuangW. The progress of molecules and strategies for the treatment of HBV infection.Front. Cell. Infect. Microbiol.202313112880710.3389/fcimb.2023.1128807 37009498
     [Google Scholar]
  13. VerrierE.R. ColpittsC.C. SureauC. BaumertT.F. Hepatitis B virus receptors and molecular drug targets.Hepatol. Int.201610456757310.1007/s12072‑016‑9718‑5 26979861
     [Google Scholar]
  14. PapatheodoridisG. DalekosG. SypsaV. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J. Hepatol.201664480080610.1016/j.jhep.2015.11.035 26678008
     [Google Scholar]
  15. KhaledifarA. Khosravi FarsaniM.R. RaeisiE. Berberine efficacy against Doxorubicin-induced cardiotoxicity: A systematic review.J Herbmed Pharmacol202312218719310.34172/jhp.2023.19
     [Google Scholar]
  16. Amini ChermahiniF. RaeisiE. AazamiM.H. MirzaeiA. HeidarianE. LemoigneY. Does bromelain-cisplatin combination afford in-vitro synergistic anticancer effects on human prostatic carcinoma cell line, PC3?Galen Med. J.20209e174910.31661/gmj.v9i0.1749 34466585
     [Google Scholar]
  17. EkorM. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety.Front. Pharmacol.2014417710.3389/fphar.2013.00177 24454289
     [Google Scholar]
  18. Ramírez-GarzaS. Laveriano-SantosE. Marhuenda-MuñozM. Health effects of resveratrol: Results from human intervention trials.Nutrients20181012189210.3390/nu10121892 30513922
     [Google Scholar]
  19. RoyA. RoyM. GacemA. Role of bioactive compounds in the treatment of hepatitis: A review.Front. Pharmacol.202213105175110.3389/fphar.2022.1051751 36618936
     [Google Scholar]
  20. IzzoC. AnnunziataM. MelaraG. The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials.Nutrients202113393310.3390/nu13030933 33805795
     [Google Scholar]
  21. KoJ.H. SethiG. UmJ.Y. The role of resveratrol in cancer therapy.Int. J. Mol. Sci.20171812258910.3390/ijms18122589 29194365
     [Google Scholar]
  22. TalibW.H. AlsayedA.R. FarhanF. Al KuryL.T. Resveratrol and tumor microenvironment: Mechanistic basis and therapeutic targets.Molecules20202518428210.3390/molecules25184282 32961987
     [Google Scholar]
  23. van BrummelenR. van BrummelenA.C. The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19 - A formulator’s perspective.Biomed. Pharmacother.202214811276710.1016/j.biopha.2022.112767 35240527
     [Google Scholar]
  24. PalamaraA.T. NencioniL. AquilanoK. Inhibition of influenza A virus replication by resveratrol.J. Infect. Dis.2005191101719172910.1086/429694 15838800
     [Google Scholar]
  25. ShaitoA. PosadinoA.M. YounesN. Potential adverse effects of resveratrol: A literature review.Int. J. Mol. Sci.2020216208410.3390/ijms21062084 32197410
     [Google Scholar]
  26. NakamuraM. SaitoH. IkedaM. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.World J. Gastroenterol.201016218419210.3748/wjg.v16.i2.184 20066737
     [Google Scholar]
  27. DengJ.J. KongK.Y.E. GaoW.W. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription.Biochim. Biophys. Acta. Gene Regul. Mech.20171860449150110.1016/j.bbagrm.2017.02.007 28242208
     [Google Scholar]
  28. Musarra-PizzoM. PennisiR. Ben-AmorI. MandalariG. SciortinoM.T. Antiviral activity exerted by natural products against human viruses.Viruses202113582810.3390/v13050828 34064347
     [Google Scholar]
  29. EversD.L. WangX. HuongS.M. HuangD.Y. HuangE.S. 3,4′,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling.Antiviral Res.2004632859510.1016/j.antiviral.2004.03.002 15302137
     [Google Scholar]
  30. GaoF. DengG. LiuW. ZhouK. LiM. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.Oncol. Rep.20173721203121110.3892/or.2017.5347 28075467
     [Google Scholar]
  31. PennisiM. BertinoG. GaglianoC. Resveratrol in hepatitis C patients treated with pegylated-interferon-α-2b and ribavirin reduces sleep disturbance.Nutrients20179889710.3390/nu9080897 28820468
     [Google Scholar]
  32. LuoH. ZhangS. Preliminary study of resveratrol on anti-hepatitis B virus and hepatitis induced fibrosis.Chinese J Biochem Pharmaceut20162932
     [Google Scholar]
  33. NakamuraM. SaitoH. IkedaM. HokariR. HibiT. MiuraS. 3,4-, 5-trihydroxy-trans-stilbene (resveratrol) enhances hepatitis c virus replication in vitro: 333.J Am Coll Gastroenterol2009104
     [Google Scholar]
  34. JiangL. GuY. YeJ. Resveratrol prevents hepatic steatosis induced by hepatitis C virus core protein.Biotechnol. Lett.201234122205221210.1007/s10529‑012‑1034‑0 22941371
     [Google Scholar]
  35. LinH.C. ChenY.F. HsuW.H. YangC.W. KaoC.H. TsaiT.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model.Cancer Prev. Res20125795296210.1158/1940‑6207.CAPR‑12‑0001 22659145
     [Google Scholar]
  36. SrisutteeR. KohS.S. KimS.J. Hepatitis B virus X (HBX) protein upregulates β-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase.Oncol. Rep.2012281276282 22562294
     [Google Scholar]
  37. SrisutteeR. KohS.S. MalilasW. SIRT1 sensitizes hepatocellular carcinoma cells expressing hepatitis B virus X protein to oxidative stress-induced apoptosis.Biochem. Biophys. Res. Commun.20124291-2455010.1016/j.bbrc.2012.10.102 23137540
     [Google Scholar]
  38. HsiehW.C. YangC.W. HaungY.S. ChaoT.W. TsaiT.F. SuI.J. Chemoprevention of HBV-related hepatocellular carcinoma by the combined product of resveratrol and silymarin in transgenic mice.Funct. Food Health Dis.20133934135210.31989/ffhd.v3i9.41
     [Google Scholar]
  39. TengC.F. HsiehW.C. WuH.C. Hepatitis B virus Pre-S2 mutant induces aerobic glycolysis through mammalian target of rapamycin signal cascade.PLoS One2015104e012237310.1371/journal.pone.0122373 25909713
     [Google Scholar]
  40. LeeS. YoonK.D. LeeM. Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.Br. J. Pharmacol.2016173119121110.1111/bph.13358 26445091
     [Google Scholar]
  41. ShiY. LiY. HuangC. Resveratrol enhances HBV replication through activating Sirt1-PGC-1α-PPARα pathway.Sci. Rep.2016612474410.1038/srep24744 27098390
     [Google Scholar]
  42. ParkS. LimJ. KimJ.R. ChoS. Inhibitory effects of resveratrol on hepatitis B virus X protein-induced hepatocellular carcinoma.J. Vet. Sci.201718441942910.4142/jvs.2017.18.4.419 28385009
     [Google Scholar]
  43. SunL.J. YuJ.W. ShiY.G. ZhangX.Y. ShuM.N. ChenM.Y. Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.J. Med. Virol.201890592693510.1002/jmv.25034 29350417
     [Google Scholar]
  44. LeeS. MailarK. KimM.I. Plant-derived purification, chemical synthesis, and in vitro/in vivo evaluation of a resveratrol dimer, viniferin, as an HCV replication inhibitor.Viruses2019111089010.3390/v11100890 31547617
     [Google Scholar]
  45. YamaiT. HikitaH. FukuokaM. SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy.Biochem. Biophys. Res. Commun.20205271647010.1016/j.bbrc.2020.04.031 32446392
     [Google Scholar]
  46. AcerbiG. MontaliI. FerrignoG.D. Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B.J. Hepatol.202174478379310.1016/j.jhep.2020.10.034 33188902
     [Google Scholar]
  47. PanP. LiJ. LinW. LongG. Effects of Resveratrol on Hepatitis B Virus Replication: In vitro and in vivo Experiments.Intervirology202265420621410.1159/000525807 36088911
     [Google Scholar]
  48. KhattarS. KhanS.A. ZaidiS.A.A. Resveratrol from dietary supplement to a drug candidate: An assessment of potential.Pharmaceuticals202215895710.3390/ph15080957 36015105
     [Google Scholar]
  49. SalehiB. MishraA. NigamM. Resveratrol: A double-edged sword in health benefits.Biomedicines2018639110.3390/biomedicines6030091 30205595
     [Google Scholar]
  50. RawsonJ.M.O. RothM.E. XieJ. Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.Bioorg. Med. Chem.201624112410242210.1016/j.bmc.2016.03.052 27117260
     [Google Scholar]
  51. AnnunziataG. MaistoM. SchisanoC. Resveratrol as a novel anti-herpes simplex virus nutraceutical agent: An overview.Viruses201810947310.3390/v10090473 30177661
     [Google Scholar]
  52. ZhaoX. CuiQ. FuQ. Antiviral properties of resveratrol against pseudorabies virus are associated with the inhibition of IκB kinase activation.Sci. Rep.201771878210.1038/s41598‑017‑09365‑0 28821840
     [Google Scholar]
  53. ChenX. SongX. LiL. Resveratrol inhibits pseudorabies virus replication by targeting IE180 protein.Front. Microbiol.20221389197810.3389/fmicb.2022.891978 35722304
     [Google Scholar]
  54. CheltsovA.V. AoyagiM. AleshinA. Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.J. Med. Chem.201053103899390610.1021/jm901446n 20441222
     [Google Scholar]
  55. LovelaceE. PolyakS. Natural products as tools for defining how cellular metabolism influences cellular immune and inflammatory function during chronic infection.Viruses20157126218623210.3390/v7122933 26633463
     [Google Scholar]
  56. YiuC.Y. ChenS.Y. ChangL.K. ChiuY.F. LinT.P. Inhibitory effects of resveratrol on the epstein-barr virus lytic cycle.Molecules201015107115712410.3390/molecules15107115 20948499
     [Google Scholar]
  57. KodeA. RajendrasozhanS. CaitoS. YangS.R. MegsonI.L. RahmanI. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells.Am. J. Physiol. Lung Cell. Mol. Physiol.20082943L478L48810.1152/ajplung.00361.2007 18162601
     [Google Scholar]
  58. TanA. KohS. BertolettiA. Immune response in hepatitis B virus infection.Cold Spring Harb. Perspect. Med.201558a02142810.1101/cshperspect.a021428 26134480
     [Google Scholar]
  59. SilvaA.M. OliveiraM.I. SetteL. Resveratrol as a natural anti-tumor necrosis factor-α molecule: Implications to dendritic cells and their crosstalk with mesenchymal stromal cells.PLoS One201493e9140610.1371/journal.pone.0091406 24614867
     [Google Scholar]
  60. GaoX. XuY.X. JanakiramanN. ChapmanR.A. GautamS.C. Immunomodulatory activity of resveratrol: Suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production.Biochem. Pharmacol.20016291299130810.1016/S0006‑2952(01)00775‑4 11705464
     [Google Scholar]
  61. KalkusovaK. TaborskaP. StakheevD. SmrzD. The role of miR-155 in antitumor immunity.Cancers20221421541410.3390/cancers14215414 36358832
     [Google Scholar]
  62. SongX. TanS. WuZ. HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation.Int. J. Cancer2018143123120313010.1002/ijc.31595 29752719
     [Google Scholar]
  63. BelloniL. PollicinoT. De NicolaF. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.Proc. Natl. Acad. Sci.200910647199751997910.1073/pnas.0908365106 19906987
     [Google Scholar]
  64. RenJ.H. TaoY. ZhangZ.Z. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1.J. Virol.20148852442245110.1128/JVI.02861‑13 24335313
     [Google Scholar]
  65. D’souzaS. LauK.C.K. CoffinC.S. PatelT.R. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma.World J. Gastroenterol.202026385759578310.3748/wjg.v26.i38.5759 33132633
     [Google Scholar]
  66. SadasivamN. KimY.J. RadhakrishnanK. KimD.K. Oxidative stress, genomic integrity, and liver diseases.Molecules20222710315910.3390/molecules27103159 35630636
     [Google Scholar]
  67. PruchniakM.P. AraźnaM. DemkowU. Biochemistry of oxidative stress.Adv. Exp. Med. Biol.201587891910.1007/5584_2015_161 26269026
     [Google Scholar]
  68. IvanovA.V. Valuev-EllistonV.T. TyurinaD.A. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis.Oncotarget2017833895393210.18632/oncotarget.13904 27965466
     [Google Scholar]
  69. ShaoM. WangY. DongH. From liver fibrosis to hepatocarcinogenesis: Role of excessive liver H2O2 and targeting nanotherapeutics.Bioact. Mater.20232318720510.1016/j.bioactmat.2022.11.001 36406254
     [Google Scholar]
  70. Pratim DasP. MedhiS. Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis.Cytokine202317015634710.1016/j.cyto.2023.156347 37639845
     [Google Scholar]
  71. BeudekerB.J.B. GroothuisminkZ.M.A. van der EijkA.A. DebesJ.D. BoonstraA. Circulating cytokines reflect the etiology-specific immune environment in cirrhosis and HCC.Cancers20221419490010.3390/cancers14194900 36230823
     [Google Scholar]
  72. PrystupaA. KicińskiP. SakJ. Boguszewska-CzubaraA. Toruń-JurkowskaA. ZałuskaW. Proinflammatory cytokines (IL-1 α IL-6) and hepatocyte growth factor in patients with alcoholic liver cirrhosis.Gastroenterol. Res. Pract.201520151710.1155/2015/532615 26448742
     [Google Scholar]
  73. TuT. BudzinskaM. ShackelN. UrbanS. HBV DNA integration: Molecular mechanisms and clinical implications.Viruses2017947510.3390/v9040075 28394272
     [Google Scholar]
  74. XiaY. GuoH. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.Antiviral Res.202018010482410.1016/j.antiviral.2020.104824 32450266
     [Google Scholar]
  75. JiangY. HanQ. ZhaoH. ZhangJ. The mechanisms of HBV-induced hepatocellular carcinoma.J. Hepatocell. Carcinoma2021843545010.2147/JHC.S307962 34046368
     [Google Scholar]
  76. AliA. Abdel-HafizH. SuhailM. Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.World J. Gastroenterol.20142030102381024810.3748/wjg.v20.i30.10238 25132741
     [Google Scholar]
  77. Al-QahtaniA.A. Al-AnaziM.R. NazirN. The correlation between hepatitis B virus precore/core mutations and the progression of severe liver disease.Front. Cell. Infect. Microbiol.2018835510.3389/fcimb.2018.00355 30406036
     [Google Scholar]
  78. WeiF. ZhengQ. LiM. WuM. The association between hepatitis B mutants and hepatocellular carcinoma.Medicine20179619e683510.1097/MD.0000000000006835 28489767
     [Google Scholar]
  79. KarabekirS.C. ÖzgörgülüA. Possible protective effects of resveratrol in hepatocellular carcinoma.Iran. J. Basic Med. Sci.20202317178 32405350
     [Google Scholar]
  80. ZengZ. CaoZ. TangY. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus associated early stage hepatocellular carcinoma based on RNA sequencing data.Oncol. Lett.2020205110.3892/ol.2020.12094 32968453
     [Google Scholar]
  81. LiY.W. YangF.C. LuH.Q. ZhangJ.S. Hepatocellular carcinoma and hepatitis B surface protein.World J. Gastroenterol.20162261943195210.3748/wjg.v22.i6.1943 26877602
     [Google Scholar]
  82. EssersM.A.G. WeijzenS. de Vries-SmitsA.M.M. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK.EMBO J.200423244802481210.1038/sj.emboj.7600476 15538382
     [Google Scholar]
  83. BhattacharyaS. PerrisA. JawedJ.J. HodaM. Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action.Pharmacol. Res. Mod. Chinese Med.2023610023310.1016/j.prmcm.2023.100233
     [Google Scholar]
  84. MukherjeeS DudleyJI DasDK Dose-dependency of resveratrol in providing health benefits.Dose Response201084dose-response.010.2203/dose‑response.09‑015.Mukherjee 21191486
     [Google Scholar]
  85. HashemiM. NadafzadehN. ImaniM.H. Targeting and regulation of autophagy in hepatocellular carcinoma: Revisiting the molecular interactions and mechanisms for new therapy approaches.Cell Commun. Signal.20232113210.1186/s12964‑023‑01053‑z 36759819
     [Google Scholar]
  86. TianY. SongW. LiD. CaiL. ZhaoY. Resveratrol as a natural regulator of autophagy for prevention and treatment of cancer.OncoTargets Ther.2019128601860910.2147/OTT.S213043 31802896
     [Google Scholar]
  87. ZhangB. YinX. SuiS. Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3 kinase/protein kinase B pathway.Oncol. Rep.20184052758276510.3892/or.2018.6648 30132535
     [Google Scholar]
  88. van GinkelP.R. SareenD. SubramanianL. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria.Clin. Cancer Res.200713175162516910.1158/1078‑0432.CCR‑07‑0347 17785572
     [Google Scholar]
  89. WuS.L. SunZ.J. YuL. MengK.W. QinX.L. PanC.E. Effect of resveratrol and in combination with 5-FU on murine liver cancer.World J. Gastroenterol.200410203048305210.3748/wjg.v10.i20.3048 15378791
     [Google Scholar]
  90. AbduS.B. Al-BogamiF.M. Influence of resveratrol on liver fibrosis induced by dimethylnitrosamine in male rats.Saudi J. Biol. Sci.201926120120910.1016/j.sjbs.2017.09.003 30622427
     [Google Scholar]
  91. MaX. SunZ. HanX. Neuroprotective effect of resveratrol via activation of sirt1 signaling in a rat model of combined diabetes and alzheimer’s disease.Front. Neurosci.202013140010.3389/fnins.2019.01400 32038127
     [Google Scholar]
  92. Lee-ChangC. WejkszaK. BodogaiM. Resveratrol abrogates tumor-evoked Bregs conversion by targeting PPAR-alpha pathway (127.41).J. Immunol.2012188S1127141
     [Google Scholar]
  93. PatelK.R. ScottE. BrownV.A. GescherA.J. StewardW.P. BrownK. Clinical trials of resveratrol.Ann. N. Y. Acad. Sci.20111215116116910.1111/j.1749‑6632.2010.05853.x 21261655
     [Google Scholar]
  94. BrownV.A. PatelK.R. ViskadurakiM. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.Cancer Res.201070229003901110.1158/0008‑5472.CAN‑10‑2364 20935227
     [Google Scholar]
  95. ChibaT. KimuraY. SuzukiS. TatefujiT. UmegakiK. Trans-resveratrol enhances the anticoagulant activity of warfarin in a mouse model.J. Atheroscler. Thromb.20162391099111010.5551/jat.31765 26947597
     [Google Scholar]
  96. Ferry-DumazetH. GarnierO. Mamani-MatsudaM. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells.Carcinogenesis20022381327133310.1093/carcin/23.8.1327 12151351
     [Google Scholar]
  97. WalleT. HsiehF. DeLeggeM.H. OatisJ.E.Jr WalleU.K. High absorption but very low bioavailability of oral resveratrol in humans.Drug Metab. Dispos.200432121377138210.1124/dmd.104.000885 15333514
     [Google Scholar]
  98. ZhengY. JiaR. LiJ. TianX. QianY. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma.J. Nanobiotechnology202220133910.1186/s12951‑022‑01554‑y 35858935
     [Google Scholar]
  99. RahmanM. AlmalkiW.H. AfzalO. Cationic solid lipid nanoparticles of resveratrol for hepatocellular carcinoma treatment: Systematic optimization, in vitro characterization and preclinical investigation.Int. J. Nanomedicine2020159283929910.2147/IJN.S277545 33262588
     [Google Scholar]
  100. HassanE.A. HathoutR.M. GadH.A. SammourO.A. Multi-purpose zein nanoparticles for battling hepatocellular carcinoma: A Green approach.Eur. Polym. J.202217611139610.1016/j.eurpolymj.2022.111396
     [Google Scholar]
  101. JoseA. BavettaM.G. MartinelliE. BronteF. GiuntaE.F. ManuK.A. Hepatocellular carcinoma: Current therapeutic algorithm for localized and advanced disease.J. Oncol.2022202211410.1155/2022/3817724 36624801
     [Google Scholar]
/content/journals/cmm/10.2174/0115665240284347240125072555
Loading
A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and Chronic Viral Hepatitis-related Hepatocellular Carcinoma
Current Molecular Medicine 25, 589 (2025); https://doi.org/10.2174/0115665240284347240125072555
/content/journals/cmm/10.2174/0115665240284347240125072555
/content/journals/cmm/10.2174/0115665240284347240125072555
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): cirrhosis; hepatitis; hepatocellular carcinoma; Resveratrol; side effect; viral replication

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test